Provided by Tiger Trade Technology Pte. Ltd.

Invivyd, Inc.

0.8300
-0.0618-6.93%
Pre-market: 0.8163-0.0137-1.65%07:33 EDT
Volume:4.23M
Turnover:3.59M
Market Cap:244.85M
PE:-2.28
High:0.8930
Open:0.8812
Low:0.8200
Close:0.8918
52wk High:3.07
52wk Low:0.5277
Shares:295.00M
Float Shares:208.00M
Volume Ratio:1.50
T/O Rate:2.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3641
EPS(LYR):-0.3048
ROE:-95.89%
ROA:-45.67%
PB:1.35
PE(LYR):-2.72

Loading ...

Invivyd Files Form 3 for CMO, Chief Epidemiologist Michael Mina

Reuters
·
Aug 05

Invivyd Grants 277,500 Inducement Stock Options to New Hires at $0.54 Exercise Price

Reuters
·
Aug 04

Invivyd Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 04

Invivyd Gets NASDAQ Notice After Shares Trade Below $1 Minimum Bid Price

Reuters
·
Jul 25

Analysts Conflicted on These Healthcare Names: Cipher Pharmaceuticals (OtherCPHRF), Invivyd (IVVD) and Merck & Company (MRK)

TIPRANKS
·
Jul 09

Invivyd Price Target Maintained with a $10.00/share by BTIG

Dow Jones
·
Jul 07

FDA to End Emergency Use Authorization for Invivyd's Covid-19 Prevention Shot

Dow Jones
·
Jul 06

Invivyd announces notice of termination for Pemgarda Emergency Use Authorization

TIPRANKS
·
Jul 06

Invivyd Says FDA Sets June 29, 2027 Termination Date for Pemgarda EUA

Reuters
·
Jul 06

Invivyd - in Dialogue with FDA on Next Steps for Pemgarda

THOMSON REUTERS
·
Jul 06

Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (eua) Termination for Pemgarda® and Provides an Update on Next Steps with the U.S. FDA

THOMSON REUTERS
·
Jul 06

Invivyd - FDA to Terminate Pemgarda Eua Effective June 29, 2027

THOMSON REUTERS
·
Jul 06

Novabridge Biosciences Appoints DR. Srishti Gupta as Chief Executive Officer

THOMSON REUTERS
·
Jun 29

Invivyd posts CANOPY older-adult subgroup analysis presentation on pemivibart for COVID-19 prevention

Reuters
·
Jun 17

Invivyd completes enrollment of LIBERTY clinical trial

TIPRANKS
·
Jun 16

Invivyd's Late-Stage Trial of Covid Vaccine Alternative Completes Enrollment; Shares Rise Pre-Bell

MT Newswires Live
·
Jun 16

Invivyd - to Report Liberty Study Results in Q3 2026

THOMSON REUTERS
·
Jun 16

Invivyd Announces Completion of Enrollment in Phase 3 Liberty Trial Evaluating Vyd2311 Antibody Versus Mrna Covid-19 Vaccine

THOMSON REUTERS
·
Jun 16

Invivyd Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 15

Invivyd Price Target Maintained With a $10.00/Share by BTIG

Dow Jones
·
Jun 10